Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Total Valuation
Protagonist Therapeutics has a market cap or net worth of $2.62B. The enterprise value is $2.16B.
Market Cap$2.62B
Enterprise Value$2.16B
Share Statistics
Protagonist Therapeutics has 61.38M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61.38M
Owned by Insiders1.78%
Owned by Instutions0.17%
Financial Efficiency
Protagonist Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is 35.69%.
Return on Equity (ROE)40.75%
Return on Assets (ROA)36.95%
Return on Invested Capital (ROIC)35.69%
Return on Capital Employed (ROCE)36.26%
Revenue Per Employee$3,447,880.952
Profits Per Employee$2,184,031.746
Employee Count126
Asset Turnover0.58
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagonist Therapeutics is 8.64. Protagonist Therapeutics’s PEG ratio is -0.02.
PE Ratio8.64
PS Ratio5.47
PB Ratio3.52
Price to Fair Value3.52
Price to FCF13.00
Price to Operating Cash Flow12.91
PEG Ratio-0.02
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of $434.43M and earned $275.19M in profits. Earnings per share was $4.51.
Revenue$434.43M
Gross Profit$432.72M
Operating Income$252.84M
Pretax Income$279.41M
Net Income$275.19M
EBITDA254.85M
Earnings Per Share (EPS)4.51
Cash Flow
In the last 12 months, operating cash flow was $184.15M and capital expenditures -$1.35M, giving a free cash flow of $182.80M billion.
Operating Cash Flow$184.15M
Free Cash Flow$182.80M
Free Cash Flow per Share$2.98
Dividends & Yields
Protagonist Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield7.69%
Earnings Yield11.58%
Stock Price Statistics
Beta0.88
52-Week Price Change79.82%
50-Day Moving Average44.00
200-Day Moving Average41.99
Relative Strength Index (RSI)48.08
Average Volume (3m)1.61M
Important Dates
Protagonist Therapeutics upcoming earnings date is Apr 30, 2025, After Close.
Last Earnings DateFeb 21, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
Protagonist Therapeutics as a current ratio of 12.48, with Debt / Equity ratio of 0.02
Current Ratio12.48
Quick Ratio12.48
Debt to Market Cap<0.01
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagonist Therapeutics has paid $4.22M in taxes.
Income Tax$4.22M
Effective Tax Rate1.51%
Enterprise Valuation
Protagonist Therapeutics EV to EBITDA ratio is 9.06, with an EV/FCF ratio of 12.53.
EV to Sales5.27
EV to EBITDA9.06
EV to Free Cash Flow12.53
EV to Operating Cash Flow12.44
Balance Sheet
Protagonist Therapeutics has $418.91M in cash and marketable securities with $10.87M in debt, giving a net cash position of -$408.05M billion.
Cash & Marketable Securities$418.91M
Total Debt$10.87M
Net Cash-$408.05M
Net Cash Per Share-$6.65
Tangible Book Value Per Share$10.97
Margins
Gross margin is 100.00%, with operating margin of 58.20%, and net profit margin of 63.34%.
Gross Margin100.00%
Operating Margin58.20%
Pretax Margin64.32%
Net Profit Margin63.34%
EBITDA Margin58.20%
EBIT Margin58.20%
Analyst Forecast
The average price target for Protagonist Therapeutics is $67.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$67.80
Price Target Upside50.57%
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast624.05%
EPS Growth Forecast